Apontis Pharma AG (FRA:APPH) PEG Ratio: N/A (As of Jul. 01, 2026)


FRA:APPH Apontis Pharma AG FRA:APPH
17 GF Score
Price €11.00
GF Value €10.46
! 7 Warning Signs
View Full Analysis

What is Apontis Pharma AG PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Apontis Pharma AG's PE Ratio without NRI is 141.03. Apontis Pharma AG's 5-Year EBITDA growth rate is 0.00%. Therefore, Apontis Pharma AG's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Apontis Pharma AG's PEG Ratio or its related term are showing as below:



FRA:APPH's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.69
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Apontis Pharma AG  (FRA:APPH) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Apontis Pharma AG PEG Ratio Related Terms


Apontis Pharma AG PEG Ratio Historical Data

* Premium members only.

The historical data trend for Apontis Pharma AG's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apontis Pharma AG PEG Ratio Chart

Apontis Pharma AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PEG Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Apontis Pharma AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:APPH vs ZTS, UTHR, NBIX: PEG Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Apontis Pharma AG's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apontis Pharma AG PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apontis Pharma AG's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Apontis Pharma AG's PEG Ratio falls into.


FRA:APPH
17GF Score
Apontis Pharma AG FRA:APPH
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apontis Pharma AG PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Apontis Pharma AG's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=141.02564102564/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Apontis Pharma AG (FRA:APPH) Overvalued in 2026?

Based on GuruFocus' analysis, Apontis Pharma AG stock appears to be overvalued. The current stock price of €11.00 is trading 5.2% above its estimated GF Value™ of €10.46.

Key valuation signals for FRA:APPH:

  • PEG Ratio: N/A
  • GF Value™: €10.46 vs. price of €11.00 (5.2% above fair value)
  • GF Score™: 17/100 with 7 warning signs

No single metric tells the full story. See the FRA:APPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Apontis Pharma AG Business Description

Address Rolf-Schwarz-Schutte-Platz 1, Monheim, BY, DEU, 40789
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.
17GF Score

Get the complete analysis for FRA:APPH

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.00
Price
€10.46
GF Value